8-K: Avalon GloboCare Receives Nasdaq Deficiency Notice

Avalon GloboCare Corp. has been notified by Nasdaq of non-compliance with the minimum $1.00 bid price requirement.

Summary

• Avalon GloboCare Corp. received a formal notification from Nasdaq on April 15, 2026, regarding non-compliance with the minimum bid price rule.
• The company failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
• The company has until October 12, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
• The common stock continues to trade on The Nasdaq Capital Market under the symbol ALBT without immediate impact.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it highlights the company's inability to maintain minimum market valuation standards, increasing the risk of delisting.

Positives

• The notification has no immediate effect on the listing or trading of the company's common stock.
• The company has a clear 180-day window to address the deficiency before facing potential delisting.

Negatives

• The company is currently in violation of Nasdaq Listing Rule 5550(a)(2).
• The stock price has failed to sustain the $1.00 threshold required for continued listing.

Risks

• Potential delisting from The Nasdaq Capital Market if compliance is not regained by October 12, 2026.
• Possible requirement to execute a reverse stock split to artificially inflate the share price to meet listing standards.
• Potential negative impact on investor sentiment and liquidity due to the deficiency notice.

Future Outlook

The company intends to monitor its stock price and may consider options, including a reverse stock split, to regain compliance with Nasdaq listing requirements.

Management Comments

• The company acknowledges the notification and is evaluating options to regain compliance, including a potential reverse stock split.

Industry Context

StockSavvy.ai notes that receiving a Nasdaq deficiency notice for bid price is a common challenge for small-cap and micro-cap biotech firms, often signaling a need for either improved operational performance or capital restructuring to maintain exchange eligibility.

Comparison to Industry Standards

• The company's struggle to maintain a $1.00 share price is consistent with many micro-cap peers in the biotechnology sector facing market volatility.
• The 180-day compliance period is a standard regulatory grace period provided by Nasdaq for companies failing to meet minimum price thresholds.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the stock's continued listing on Nasdaq.
• Potential for share dilution if a reverse stock split is implemented.

Next Steps

• Monitor the closing bid price of the common stock.
• Evaluate the necessity of a reverse stock split to regain compliance.
• Work toward meeting the $1.00 minimum bid price for 10 consecutive business days before October 12, 2026.

Key Dates

Recommendation

The receipt of a deficiency notice often precedes significant volatility and potential dilutive actions like reverse stock splits, which typically weigh heavily on shareholder value in the short to medium term.

Keywords

Avalon GloboCare, ALBT, Nasdaq, Delisting, Minimum Bid Price, Compliance, Reverse Stock Split